|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University of Pittsburgh Merck |
| Information provided by: | University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00360282 |
Purpose
The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
| Condition | Intervention | Phase |
|
Migraine |
Drug: Rizatriptan |
Phase 0 |
| Genetics Home Reference related topics: | familial hemiplegic migraine |
| MedlinePlus related topics: | Migraine Motion Sickness |
| ChemIDplus related topics: | Rizatriptan Benzoate Rizatriptan |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study |
| Official Title: | Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs |
| Estimated Enrollment: | 25 |
| Study Start Date: | August 2006 |
| Estimated Study Completion Date: | January 2009 |
| Estimated Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Migraine sufferers undergo vestibular tests to note abnormalities. There are 2 experimental visits in which migraine sufferers are given either the Rizatriptan or a fake pill and then are asked to rotate in a chair that is tilted. Motion sickness scores are taken throughout testing.
Eligibility
| Ages Eligible for Study: | 21 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Susan Strelinski | (412) 647-8088 | strelinskisb@upmc.edu |
| Contact: Anita Lieb, MS, CCRC | (412) 647-8087 | alieb@pitt.edu |
| United States, Pennsylvania | |||||
| University of Pittsburgh | Recruiting | ||||
| Pittsburgh, Pennsylvania, United States, 15213 | |||||
| Principal Investigator: Joseph M Furman, MD, PhD | |||||
| Sub-Investigator: Dawn Marcus, MD | |||||
| University of Pittsburgh |
| Merck |
| Principal Investigator: | Joseph M Furman, MD, PhD | University of Pittsburgh |
More Information
| Responsible Party: | University of Pittsburgh ( Dr. Joseph Furman ) |
| Study ID Numbers: | 0602009, Merck31449 |
| First Received: | August 2, 2006 |
| Last Updated: | February 6, 2008 |
| ClinicalTrials.gov Identifier: | NCT00360282 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|